Adial Pharmaceuticals, Inc. (ADIL)
$
0.37
-0.01 (-2.70%)
Key metrics
Financial statements
Free cash flow per share
-0.6103
Market cap
8 Million
Price to sales ratio
14.2 Thousand
Debt to equity
0
Current ratio
5.0194
Income quality
0.9986
Average inventory
0
ROE
-1.9129
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapeutics aimed at treating or preventing addiction and related disorders. Its lead product, AD04, is a selective serotonin-3 antagonist currently undergoing Phase III clinical trials for the treatment of alcohol use disorder. The company earned an interest income of $178,659.00 showcasing its financial investments which position it for future growth. The net income ratio is 0.00 reflecting the company's profitability margin in the competitive biopharmaceutical landscape. Highlighting its shareholder base, the weighted average number of shares outstanding is 18,588,748.00. Furthermore, the EBITDA ratio is 0.00 showcasing the company's operational efficiency in managing resources and expenses effectively. The earnings per share (EPS) is reported at -$0.71 indicating the company's profitability on a per-share basis, which is a crucial metric for potential investors. Adial Pharmaceuticals is also dedicated to developing drug candidates for non-opioid pain reduction and various other diseases and disorders, further expanding its portfolio of potential solutions to pressing health issues. Founded in 2010 and based in Charlottesville, Virginia, the company is committed to advancing its innovative therapeutics. The stock is affordable at $0.37 making it suitable for budget-conscious investors looking to enter the biopharmaceutical market. However, the stock has a low average trading volume of 9,174,254.00 indicating lower market activity, which could suggest a need for increased investor interest. With a market capitalization of $7,997,402.00 the company is classified as a small-cap player within the industry, allowing it to focus on specialized areas of research and development. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape with its unique focus on addiction therapies. Moreover, it belongs to the Healthcare sector, driving innovation and growth in a field that is increasingly recognized for its importance in public health. This positioning enables Adial Pharmaceuticals to potentially make impactful advancements in therapeutic options for individuals affected by addiction and related disorders.
Is Adial Pharmaceuticals, Inc. (ADIL) a good investment?
Investing in Adial Pharmaceuticals, Inc. (ADIL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Adial Pharmaceuticals, Inc. (ADIL)'s stock forecast?
Analysts predict Adial Pharmaceuticals, Inc. stock to fluctuate between $0.22 (low) and $1.30 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Adial Pharmaceuticals, Inc.'s market capitalization?
As of 2025-08-20, Adial Pharmaceuticals, Inc.'s market cap is $7,997,402, based on 21,614,600 outstanding shares.
How does Adial Pharmaceuticals, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Adial Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Adial Pharmaceuticals, Inc. (ADIL) stock?
To buy Adial Pharmaceuticals, Inc. (ADIL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ADIL. Place an order (Market, Limit, etc.).
What is the best time to invest in Adial Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Adial Pharmaceuticals, Inc. stock ever split?
Adial Pharmaceuticals, Inc.'s last stock split was 1:25 on 2023-08-07.
How did Adial Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.71 | Growth: -86.95%.
Where can I find Adial Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.adialpharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Adial Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Adial Pharmaceuticals, Inc. stock?
All-time high: $127 (2021-09-24) | All-time low: $0.22 (2025-06-18).
What are the key trends affecting Adial Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2025.
zacks.com
Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
globenewswire.com
GLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the filing of an update to the provisional patent application for AD04 which was filed in July 2024, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day).
globenewswire.com
Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical, Registration And Validation Batches of AD04 for US Clinical Trials And NDA Submission GLEN ALLEN, Va., June 25, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the recent execution of agreements for the production of AD04 (0.33 mg ondansetron tablets), supporting both the completion of upcoming clinical trials and the planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for the treatment of Alcohol Use Disorder (AUD) in the US.
globenewswire.com
GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2025.
globenewswire.com
Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar Market Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar Market
globenewswire.com
GLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of the Company for the immediate exercise of existing Series B Warrants (the "Series B Warrants") to purchase up to 1,418,440 shares of the Company's common stock, par value $0.001 per share (the “Common Stock”), and Series C Warrants (the "Series C Warrants", and together with the Series B Warrants the "Existing Warrants") to purchase up to 2,300,000 shares of Common Stock at a reduced exercise price of $0.74 for gross cash proceeds of approximately $2.75 million, before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
globenewswire.com
GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2024 fiscal year ended December 31, 2024.
globenewswire.com
Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is expected to facilitate ongoing partnership discussions
globenewswire.com
GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12150931 was issued on November 26, 2024 by the United States Patent and Trademark Office, expanding the Company's intellectual property coverage.
See all news
